Literature DB >> 25679339

Refractory metastasis of cutaneous angiosarcoma showing complete response to pazopanib.

Susumu Fujiwara, Hiroshi Nagai, Yuji Nakamachi, Seiji Kawano, Chikako Nishigori.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25679339     DOI： 10.1684/ejd.2014.2451

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN： 1167-1122            Impact factor:   3.328


× No keyword cloud information.
  2 in total

1.  Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma.

Authors:  Dai Ogata; Hiroto Yanagisawa; Kenji Suzuki; Kohei Oashi; Naoya Yamazaki; Tetsuya Tsuchida
Journal:  Med Oncol       Date:  2016-09-09       Impact factor: 3.064

2.  A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol).

Authors:  Kohei Oashi; Taro Shibata; Kenjiro Namikawa; Akira Takahashi; Kenji Yokota; Eiji Nakano; Yukiko Teramoto; Arata Tsutsumida; Taku Maeda; Naoya Yamazaki
Journal:  BMC Cancer       Date:  2020-07-13       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.